GlassScriptPhysician profile
Douglas B Mcquaid
NPI 1124230776
$2,371.90
in general payments reported to CMS, 2019-2025
30 companies · $14.04 in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,043 · 2020: $107 · 2021: $269 · 2022: $112 · 2023: $481 · 2024: $345 · 2025: $14.04.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $841.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $840.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $370.59 | 2019-2024 | Arexvy, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $284.02 | 2019-2024 | Ofev |
| Astrazeneca Pharmaceuticals LP | $279.33 | 2019-2023 | Andexxa, Tezspire, Breztri |
| Inari Medical, INC. | $233.52 | 2021 | |
| Genzyme Corporation | $177.79 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $156.63 | 2019-2023 | Zerbaxa, Dificid, Recarbrio |
| Actelion Pharmaceuticals US, INC. | $119.00 | 2019-2020 | |
| Philips North America LLC | $108.10 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $106.23 | 2019-2023 | |
| Inogen, INC. | $63.76 | 2022-2024 | |
| Mylan Specialty L.P. | $58.19 | 2019-2023 | Yupelri |
| Genentech USA, INC. | $58.13 | 2019 | |
| Grifols USA, LLC | $38.55 | 2019-2024 | Prolastin-C Liquid |
| United Therapeutics Corporation | $37.83 | 2022-2023 | Tyvaso |
| Insmed, INC. | $28.90 | 2019-2024 | Arikayce |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $25.60 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $25.57 | 2019 | |
| Electromed, INC. | $22.93 | 2024 | Smartvest |
| Baxter Healthcare | $21.84 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Ferring Pharmaceuticals INC. | $19.61 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.55 | 2024 | Glassia |
| Bioxcel Therapeutics, INC. | $17.33 | 2023 | Igalmi |
| Abbvie INC. | $16.72 | 2023 | |
| Portola Pharmaceuticals, LLC | $16.56 | 2019 | |
| La Jolla Pharmaceutical Company | $15.17 | 2020 | |
| Amgen INC. | $14.38 | 2023 | Tezspire |
| Verona Pharma, INC. | $14.04 | 2025 | Ohtuvayre |
| Quidel Corporation | $11.68 | 2019 | |
| Teleflex LLC | $11.35 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Mcquaid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.